Related Experiment Video
Updated: Mar 3, 2026

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
Published on: May 17, 2024
Monoclonal Gammopathy-Associated Peripheral Neuropathy: Diagnosis and Management
Hafsa M Chaudhry1, Michelle L Mauermann2, S Vincent Rajkumar3
1Mayo Clinic School of Medicine, Mayo Clinic, Rochester, MN.
Abstract:
Monoclonal gammopathies comprise a spectrum of clonal plasma cell disorders that include monoclonal gammopathy of undetermined significance, multiple myeloma, and Waldenström macroglobulinemia. In this review, we outline the epidemiology, etiology, classification, diagnosis, and treatment of monoclonal gammopathy-associated peripheral neuropathy. Monoclonal gammopathy of undetermined significance is relatively common in the general population, with a prevalence of 3% to 4% among individuals older than age 50 years. Therefore, the presence of M protein in a patient with neuropathy does not automatically indicate a causal relationship. Monoclonal gammopathy-associated peripheral neuropathy is often a difficult diagnosis with limited treatment options. Studies addressing the optimal approach to diagnosis and management of this entity are limited. In addition to a review of the literature, we present a diagnostic approach to patients with monoclonal gammopathy-associated peripheral neuropathy and discuss available data and options for treatment.
Related Concept Videos
Peripheral Artery Disease IV: Nursing Management
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
Nephrotic Syndrome II : Assessment and Medical Management
Peripheral Artery Disease V: Postoperative Nursing Management
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Nephrotic Syndrome III : Nursing Management

